Everything below concerns GLP-1 receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| 分子类型 | 合成修饰肽 | 39 个氨基酸，含脂肪酸侧链 |
| 受体靶点 | GIP 与 GLP-1 受体 | 双重激动剂 |
| 分子量 | 约 4.8 kDa | 以游离肽计 |
| 外观 | 白色至类白色粉末 | 冻干形态常见 |
| 溶解性 | 可溶于水及水性缓冲液 | 溶解后宜低温保存 |
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Often, when British allies attempted military actions within several dozen miles or so of the sea, the Royal Navy would arrive, land troops and supplies, and aid the coalition's land forces in a concerted operation. Royal Navy ships even provided artillery support against French units when fighting strayed near enough to the coastline. The ability and quality of the land forces governed these operations. For example, when operating with inexperienced guerrilla forces in Spain, the Royal Navy sometimes failed to achieve its objectives because of the lack of manpower that the Navy's guerrilla allies had promised to supply.
Signaling peptide receptor is a type of receptor which binds one or more signaling peptides or signaling proteins. An example is the tropomyosin receptor kinase B (TrkB), which is bound and activated by the neurotrophic protein brain-derived neurotrophic factor (BDNF). Another example is the μ-opioid receptor (MOR), which is bound and activated by the opioid peptide hormone β-endorphin.
==== Novel benzodiazepines ==== Analogues of novel benzodiazepines are able to possess antibacterial activities. When they are tested against various bacterial strains, the isoxazolyl analogues with the p-chlorophenyl group (p-CIC6H4) attached have shown to be the most effective agent against the majority of the strains. Furthermore, attachment of an electron withdrawing groups and heterocyclic rings such as thiophene and furan will increase the inhibitory effect against bacteria. Novel benzodiazepines can also modulate the Central Nervous System by docking to the human dopamine transporter D3. Enantiomers of imidazole [1,4] diazepines with either a methyl group (CH3) or a propyl group attached enhance the binding affinity towards human dopamine D3 receptors.
==== Writers and Erasers ==== The proteins that regulate genetics are often categorized as writers, readers, and erasers, i.e., enzymes that install epigenetic modifications, proteins that recognize these modifications, and enzymes that remove these modifications. To date, O-GlcNAc has been identified on writer and eraser enzymes. O-GlcNAc is found in multiple locations on EZH2, the catalytic methyltransferase subunit of PRC2, and is thought to stabilize EZH2 prior to PRC2 complex formation and regulate di- and tri-methyltransferase activity. All three members of the ten-eleven translocation (TET) family of dioxygenases (TET1, TET2, and TET3) are known to be modified by O-GlcNAc. O-GlcNAc has been suggested to cause nuclear export of TET3, reducing its enzymatic activity by depleting it from the nucleus. O-GlcNAcylation of HDAC1 is associated with elevated activating phosphorylation of HDAC1.
Mammals serve a major role in science as experimental animals, both in fundamental biological research, such as in genetics, and in the development of new medicines, which must be tested exhaustively to demonstrate their safety. Millions of mammals, especially mice and rats, are used in experiments each year. A knockout mouse is a genetically modified mouse with an inactivated gene, replaced or disrupted with an artificial piece of DNA. They enable the study of sequenced genes whose functions are unknown. A small percentage of the mammals are non-human primates, used in research for their similarity to humans. Despite the benefits domesticated mammals had for human development, humans have an increasingly detrimental effect on wild mammals across the world. It has been estimated that the mass of all wild mammals has declined to only 4% of all mammals, with 96% of mammals being humans and their livestock now (see figure). In fact, terrestrial wild mammals make up only 2% of all mammals.
Sources: en.wikipedia.org
=== Host immune response === Fibroblasts from different anatomical sites in the body express many genes that code for immune mediators and proteins. These mediators of immune response enable the cellular communication with hematopoietic immune cells. The immune activity of non-hematopoietic cells, such as fibroblasts, is referred to as "structural immunity". In order to facilitate a fast response to immunological challenges, fibroblasts encode crucial aspects of the structural cell immune response in the epigenome.
== Veterinary use == Remifentanil has a very short half-life and quick onset with recovery occurring in a few minutes regardless of length and dosage provided. Remifentanil is more effective in dogs than cats, although an increase in the dosage in cats can achieve equivalent analgesia and anti-nociception. The half-life is 6 minutes in the dog. This half-life does not increase with increased dosage or prolonged usage and thus remifentanil recovery is very quick. Hyperalgesia and tolerance has been demonstrated in rodents and rabbits but not dogs and cats. In equines remifentanil can provide long-lasting sedation when combined with xylazine and used as constant rate infusion.
Technology companies have built electricity and artificial intelligence infrastructure to facilitate the AI boom of the 2020s. A 2025 report from the consulting firm McKinsey & Company estimated that by 2030, $2.7 trillion would be invested into AI infrastructure and data centres in the US, surpassing World War II's Manhattan Project every month. In January 2024, the International Energy Agency (IEA) released Electricity 2024, Analysis and Forecast to 2026. This is the first IEA report to make projections for data centres and power consumption by AI and cryptocurrency. The report states that power demand for these uses might double by 2026, with the additional power consumption equaling that of Japan. Power consumption by AI is responsible for an increase in fossil fuel use, and has delayed closings of obsolete, carbon-emitting coal energy facilities. A ChatGPT search involves 10 times as much electrical energy as a Google search. A 2024 Goldman Sachs research paper, AI Data Centers and the Coming US Power Demand Surge, found "US power demand (is) likely to experience growth not seen in a generation...." and forecasts that, by 2030, US data centres will consume 8% of US power, as opposed to 3% in 2022, presaging growth for the electrical power generation industry by a variety of means. Data centres' need for more and more electrical power is such that they might max out the electrical grid. The Big Tech companies counter that AI can be used to maximise the utilisation of the grid by all.
==== Annexation of Subcarpathian Ruthenia by the Soviet Union ==== In October 1944, Subcarpathian Ruthenia was taken by the Soviets. A Czechoslovak delegation under František Němec was dispatched to the area. The delegation was to mobilize the liberated local population to form a Czechoslovak army and to prepare for elections in cooperation with recently established national committees. Loyalty to a Czechoslovak state was tenuous in Carpathian Ruthenia. Beneš's proclamation of April 1944 excluded former collaborationist Hungarians, Germans and the Rusynophile Ruthenian followers of Andrej Bródy and the Fencik Party (who had collaborated with the Hungarians) from political participation. This amounted to approximately 1⁄3 of the population. Another 1⁄3 was communist, leaving 1⁄3 of the population presumably sympathetic to the Czechoslovak Republic. Upon arrival in Subcarpathian Ruthenia, the Czechoslovak delegation set up headquarters in Khust, and on 30 October issued a mobilization proclamation. Soviet military forces prevented both the printing and the posting of the Czechoslovak proclamation and proceeded instead to organize the local population. Protests from Beneš's government were ignored. Soviet activities led much of the local population to believe that Soviet annexation was imminent. The Czechoslovak delegation was also prevented from establishing a cooperative relationship with the local national committees promoted by the Soviets.
== Contents == Like mainstream smoke, sidestream tobacco smoke is made up of many components including carbon monoxide, tar, nicotine, ammonia, benzene, cadmium and 4-aminobiphenyl. Some of the other compounds found in sidestream smoke are: vinylchloride, hydrogen cyanide, arsenic, acrolein, acetaldehyde, formaldehyde, catechol, cresol, hydroquinone, lead, methyl ethyl ketone, nitric oxide, phenol, styrene, toluene, and butane. Exposure to sidestream smoke yields higher concentrations of these compounds as well as increased concentrations of carboxyhemoglobin, nicotine, and cotinine in the blood. When comparing sidestream and mainstream condensate, sidestream has 2–6 times more condensate per gram than mainstream smoke. Due to the incomplete combustion process responsible for the creation of sidestream smoke, there may be exposure to higher concentrations of carcinogens than are typically inhaled directly.
Sources: en.wikipedia.org
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。
分子上的脂肪酸侧链使其与血浆白蛋白结合增强，显著延长循环半衰期。半衰期延长后，稳定血药浓度可在较长的给药间隔内维持，因此常见用法为每周一次。
同时激活两条肠促胰素通路可能在胰岛素分泌、胃排空和食欲调节上产生叠加效应。与单靶点相比，临床研究中观察到的血糖与体重变化幅度通常更明显，但各通路的具体贡献比例尚无定论。
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.